Medpace (NASDAQ:MEDP) Price Target Raised to $624.00

27 Jul 2026, 01:42 by Doug Wharley · The Cerbat Gem

Medpace (NASDAQ:MEDP – Free Report) had its price target increased by Robert W. Baird from $547.00 to $624.00 in a research report sent to investors on Friday, Marketbeat reports. Robert W. Baird currently has a neutral rating on the stock.

Several other research analysts also recently commented on MEDP. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada reduced their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday. Finally, BMO Capital Markets increased their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $560.92.

View Our Latest Stock Report on MEDP

Medpace Price Performance

Shares of MEDP opened at $601.38 on Friday. The firm has a market cap of $16.78 billion, a P/E ratio of 35.25, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. Medpace has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a 50 day simple moving average of $492.09 and a two-hundred day simple moving average of $493.84.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace will post 17.59 earnings per share for the current year.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. BOKF NA lifted its stake in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the last quarter. Valeo Financial Advisors LLC grew its position in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. increased its stake in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares during the period. Schulhoff & Co. Inc. increased its stake in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after purchasing an additional 25 shares during the period. Finally, Kaufman Rossin Wealth LLC lifted its position in shares of Medpace by 3.4% during the fourth quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after purchasing an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

More Medpace News

Here are the key news stories impacting Medpace this week:

Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.